Certain bacteria may increase the risk of fungal colonization in cystic fibrosis (CF) patients, according to a study in Germany. CF makes a patient susceptible to chronic airway inflammation and infections, resulting in lung tissue damage. Scientists have long known that bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus play roles…
News
Evaluating patients with cystic fibrosis (CF) before they board a flight may help predict whether they will need supplemental oxygen while in the air to prevent a severe decrease in blood oxygen levels, according to a study. The research, “Pre-Flight Evaluation Of Adult Patients With Cystic Fibrosis: A Cross-Sectional Study,” was…
Researchers are developing a compact respiratory device that will allow children whose lungs have failed from cystic fibrosis (CF) or other diseases to move about a hospital rather than having to stay in a bed during treatment or while awaiting a transplant. The Ambulatory Assist Lung for Children project…
Phase 1 Trial of Peptide to Treat All CF Patients (SPX-101) Shows Safety, Phase 2 Study Planned
Spyryx Biosciences successfully completed a Phase 1 clinical trial of its lead compound, SPX-101, in healthy volunteers and is now planning a Phase 2 study in patients with cystic fibrosis (CF). SPX-101 is an inhaled SPLUNC1-derived peptide created to regulate epithelial ion channels in the airways. The drug was…
Online vlogs — the video equivalents of web journals or blogs — can be an important platform for patients and families living with chronic diseases like cystic fibrosis (CF), a way of connecting with and learning from others in similar circumstances, researchers report. These vlogs, done by patients and addressing all aspects of life with a…
Three Stanford University School of Medicine researchers have won grants to advance the development of stem cell-based therapies, including gene editing, for cystic fibrosis (CF), autoimmune disorders and liver disease. The grants are part of $20.5 million awarded to 11 researchers by the California Institute for Regenerative Medicine (CIRM) during the current…
Galapagos dosed the first cystic fibrosis (CF) patient with GLPG2222, its novel CF corrector, in a Phase 2a clinical trial evaluating the drug as an add-on therapy to Kalydeco (ivacaftor) in CF patients harboring one F508del CFTR mutation and one gating mutation. The ALBATROSS Phase 2a clinical trial…
Guidelines for diagnosing cystic fibrosis (CF) were recently updated to give doctors firmer direction in determining signs of this disease, especially in those not diagnosed as newborns, and in being able to recommend the best treatment for each patient. The update, the work of 32 experts from nine countries, includes more information on mutations…
An Ohio cystic fibrosis (CF) patient was given an infusion of adult stem cells in a pioneering study that researchers hope will lead to therapies that reduce inflammation and infections linked to the disease. “I am hoping the future generations of CF patients can get better treatments and that eventually a cure…
The top 10 priorities for cystic fibrosis research — set by CF patients and specialists alike — range from learning more about treatments that delay or prevent disease progression, to simplifying therapies so they’re less burdensome and getting patients to keep using a prescribed medication, according to a survey exercise led by scientists at The University…
Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Recent Posts
- Everyday factors influence activity levels in children with cystic fibrosis February 5, 2026
- Guest Voice: Hiding CF exacerbations so people don’t feel sorry for me February 4, 2026
- Scientists ID new way to help predict, track CF-related diabetes February 3, 2026
- Severe CF flareups cause temporary pulmonary hypertension in 1 in 4 kids February 2, 2026
- Managing menopause alongside CF is uncharted territory February 2, 2026